ong-term Outcome of Intravitreal Ranibizumab Treatment, Compared with Photodynamic Therapy, in Patients with Polypoidal Choroidal Vasculopathy
Not Applicable
- Conditions
- polypoidal choroidal vasculopathy
- Registration Number
- JPRN-UMIN000008630
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who underwent PDT that was subsequently switched to ranibizumab monotherapy within 2 years were also excluded. Patients with eye diseases that could potentially influence visual acuity.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The BCVA between the pre- and postoperative BCVA at 3, 6, 12, 18, and 24 months after the initial treatment.
- Secondary Outcome Measures
Name Time Method The differences between the pre- and postoperative BCVA. The regression of polyps Complications